Where the openings are: vaccines, insulin, medical devices, raw materials and joint ventures in Pakistan’s pharma sector.
The July 2026 B2B conference ended with contracts and MoUs focused on local production of vaccines, pharmaceutical raw materials and medical devices.
Pakistan’s first vaccine policy starts with fill-and-finish and aims for full production. With Gavi support ending in 2031, the clock is running.
Zavod Medsintez and Genetics Pharmaceuticals plan an aseptic filling plant by 2028 and insulin API production by 2031.
A May 2026 summit set a goal of local manufacture of at least 30% of medical devices by 2030, with a proposed Rs1 billion R&D fund.
Five multinationals divested local manufacturing over three years, while national companies now hold nearly 80% of the market.
